Free Trial
NASDAQ:TERN

Terns Pharmaceuticals (TERN) Stock Price, News & Analysis

Terns Pharmaceuticals logo
$8.23 +0.20 (+2.49%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$8.28 +0.05 (+0.61%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Terns Pharmaceuticals Stock (NASDAQ:TERN)

Advanced

Key Stats

Today's Range
$8.01
$8.32
50-Day Range
$5.47
$8.23
52-Week Range
$1.87
$8.46
Volume
853,673 shs
Average Volume
1.04 million shs
Market Capitalization
$720.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.49
Consensus Rating
Hold

Company Overview

Terns Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

TERN MarketRank™: 

Terns Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 261st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Terns Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Terns Pharmaceuticals has a consensus price target of $15.49, representing about 88.2% upside from its current price of $8.23.

  • Amount of Analyst Coverage

    Terns Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Terns Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Terns Pharmaceuticals is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Terns Pharmaceuticals is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Terns Pharmaceuticals has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Terns Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.94% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Terns Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Terns Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.94% of the float of Terns Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Terns Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Terns Pharmaceuticals has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Terns Pharmaceuticals has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Terns Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    21 people have searched for TERN on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,410.00 in company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Terns Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Terns Pharmaceuticals' insider trading history.
Receive TERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TERN Stock News Headlines

Terns Pharmaceuticals: Valued As If It Can't Win
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
2 Under-the-Radar Stocks That Could Soar
See More Headlines

TERN Stock Analysis - Frequently Asked Questions

Terns Pharmaceuticals' stock was trading at $5.54 on January 1st, 2025. Since then, TERN stock has increased by 48.6% and is now trading at $8.23.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) released its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02.

Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

Last Earnings
8/05/2025
Today
10/03/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TERN
CIK
1831363
Fax
N/A
Employees
40
Year Founded
2017

Price Target and Rating

High Price Target
$20.00
Low Price Target
$7.44
Potential Upside/Downside
+87.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-27.35%
Return on Assets
-26.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
24.70
Quick Ratio
24.70

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
2.03

Miscellaneous

Outstanding Shares
87,510,000
Free Float
86,198,000
Market Cap
$722.40 million
Optionable
Not Optionable
Beta
-0.03

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:TERN) was last updated on 10/4/2025 by MarketBeat.com Staff
From Our Partners